Quest Diagnostics licenses technology underlying SensiTrop HIV co-receptor tropism test from pathway diagnostics -First national diagnostic testing company to license proprietary technology-.
Publication Date: 01-SEP-07
Publication Title: BIOTECH Patent News
Format: Online

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Quest Diagnostics Incorporated (Madison, NJ), the nation's leading provider of diagnostic testing, information and services, announced that it has entered into a non- exclusive license agreement for the heteroduplex tracking technology underlying Pathway Diagnostics' SensiTrop HIV co-receptor tropism test. Tropism refers to the way a virus targets host cells. A molecular-based assay for HIV co-receptor tropism will help physicians personalize therapy for HIV patients. Quest Diagnostics is the first full-service national clinical laboratory in the United States to license the technology. Terms of the agreement were not disclosed.

"Pathway Diagnostics' heteroduplex tracking technology is an important new advance that highlights the growing importance of diagnostics to personalized medicine," said Joyce G. Schwartz, M.D., vice president...



More articles from BIOTECH Patent News
University of Southern California obtains United States patent., September 01, 2007
Celtrix obtains United States patent., September 01, 2007
Monsanto obtains United States patent., September 01, 2007
ProChon obtains United States patent., September 01, 2007
Degussa obtains United States patent., September 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.